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Dog ticks (also called wood ticks) are capable of spreading the agents 
of tularemia and Rocky Mountain spotted fever.
The adult stage of the female dog tick most frequently bites humans. 
The highest risk of being bitten by a dog tick occurs during the spring 
and summer.
The adult female dog tick has a dark brown body with whitish markings 
on its dorsal scutum (plate) located behind the mouthparts.
Unfed adult dog ticks are the size of a watermelon seed.
Deer ticks are capable of spreading the agents of Lyme disease, 
human granulocytic anaplasmosis/ehrlichiosis (HGA) and babesiosis.
The nymph and adult female stages of the deer tick most frequently bite 
humans.  The greatest risk of being bitten exists throughout the spring, 
summer and fall. However, deer tick adults may be out searching for a 
host any time winter temperatures are above freezing.
The adult female deer tick has a reddish-brown tear-drop shaped 
body with a dark brown dorsal scutum (plate) located behind the 
mouthparts.
Unfed deer tick nymphs are the size of a poppy seed and unfed adults 
are the size of a sesame seed.
Ticks are generally found in brushy or wooded areas, near the ground; they cannot jump or fly.  Ticks are attracted to a variety of host factors 
including body heat and carbon dioxide.  They will transfer to a potential host when one brushes directly against them and then seek a site for 
attachment.
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Algorithm
Tick ID
Algorithm for DifferentiAting tickborne DiseAses in mAssAchusetts
This algorithm is intended for use as a general guide when pursuing a diagnosis. It does not replace the physician’s clinical judgment or the 
need for definitive laboratory testing.
Blood smear 
review
Complete Blood 
Count (CBC)
Patient resides, works, or recreates in an area likely to have ticks and is exhibiting 
fever, headache, malaise and/or lymphadenopathy
Does the patient have a rash?
Yes No
Parasites in RBC*
Babesiosis             
*If patient has an international 
travel history, malaria should be 
ruled out
Morulae in WBC
Consider human granulocytic 
anaplasmosis/
ehrlichiosis, further tests may be 
indicated
Maculopapular
Consider human granulocytic 
anaplasmosis/ehrlichiosis, further 
tests may be indicated 
Erythema migrans
Lyme disease
Normal CBC
Consider RMSF*, tularemia** or 
Lyme disease,
further tests may be indicated
* RMSF -- thrombocytopenia 
may occur
** tularemia -- WBC normal or 
elevated, thrombocytopenia 
may occur
summer fever algoriThm
other consiDerAtions
•	 Rash	occurs	in	70-80%	of	Lyme	disease	patients	and	in	10%	or	less	of	HGA	patients.
•	 Rash	occurs	in	70-80%	of	RMSF	patients	but	only	appears	several	days	after	onset	of	febrile	illness.
•	 Hyponatremia	may	occur	with	RMSF	or	tularemia.
•	 Lyme	disease	can	present	as	Bell’s	palsy,	further	tests	may	be	indicated.
•	 Ulceroglandular	tularemia	usually	presents	as	regional	lymphadenopathy	with	a	small	ulceration	distally,	further	tests	may	be	indicated.
•	 Coinfections	involving	Lyme	disease,	babesiosis,	and/or	HGA	may	occur	because	a	single	deer	tick	may	carry	multiple	pathogens.	
•	 Consider	pneumonic	tularemia	in	any	patient	presenting	with	community-acquired	pneumonia	who	resides	on,	or	has	recently	visited,	Martha’s	Vineyard.
Cutaneous ulcer
Consider tularemia 
(ulceroglandular), further tests may 
be indicated
Maculopapular to Petechial*
Consider RMSF, further tests may 
be indicated
*If petechial rash of palms and 
soles (characteristic of RMSF) 
is present, treat immediately. 
Normal hematocrit, 
thrombocytopenia, leukopenia
Consider human granulocytic 
anaplasmosis/ehrlichiosis, further 
tests may be indicated
WBC low or normal, 
thrombocytopenia, 
low hematocrit, 
elevated reticulocytes
Consider babesiosis, further tests 
may be indicated
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lAte DisseminAteD stAge (within months post-exposure )
•	 Prolonged	episodes	of	arthritis	
•	 Peripheral	enthesopathy
•	 Periostitis	or	joint	subluxations	below	acrodermatitis
•	 Chronic	axonal	polyradiculopathy
•	 Spastic	parapareses
•	 Ataxic	gait
•	 Chronic	encephalomyelitis
•	 Subtle	mental	disorders
•	 Keratitis
•	 Fatigue
lYme Disease AgentBACtERIA:  borrelia burgdorferi
eArly locAlizeD stAge (within 3-30 DAys post-exposure)
•	 Erythema	migrans	(EM)	–	red	ring-like	or	homogenous	expanding	rash	(this	is	
a pathognomonic sign)
•	 Flu-like	symptoms	including	malaise,	fatigue,	headache,	fever,	chills,	myalgia,	
regional lymphadenopathy
eArly DisseminAteD stAge (within DAys to weeks post-exposure)
•	 Severe	malaise	and	fatigue
•	 Multiple	secondary	annular	rashes
•	 Regional	or	generalized	lymphadenopathy
•	 Migratory	pain	in	joints,	tendons,	bursae,	muscle	and	bone
•	 Transient,	migratory	arthritis
•	 Atrioventricular	nodal	block
•	 Myopericarditis
•	 Pancarditis
•	 Meningitis,	motor	and	sensory	radiculoneuritis,	subtle	encephalitis,	
mononeuritis multiplex, pseudotumor cerebri
•	 Bell’s	palsy	or	other	cranial	nerve	neuritis
•	 Mild	or	recurrent	hepatitis
•	 Splenomegaly
•	 Microsopic	hematuria	or	proteinuria
common finDings on routine lAborAtory tests
•	 Elevated	sedimentation	rate	(generally	with	localized	or	early	disseminated	
disease)
•	 Mildly	elevated	hepatic	transaminases	(generally	with	early	localized	or	early	
disseminated disease)
•	 For	cases	of	Lyme	disease	meningitis,	CSF	typically	has	a	lymphocytic	
pleocytosis with slightly elevated protein levels and normal glucose levels
DiAgnostic lAborAtory criteriA
•	 Demonstration	of	diagnostic	IgM	or	IgG	antibodies	in	serum	or	cerebrospinal	
fluid.		Due	to	high	false-positive	rates	in	both	enzyme	immunoassay	(EIA)	
and	immunofluorescence	assay	(IFA)	tests,	a	two-tier	testing	protocol	is	
recommended;	a	positive	or	equivocal	EIA	or	IFA	should	be	followed	by	a	
Western blot; or
•	 Isolation	of	organism	from	a	clinical	specimen.
limitAtions to serologic tests for lyme DiseAse:  
•	 Serologic	tests	are	insensitive	during	the	first	few	weeks	of	infection.
•	 In	persons	with	illness	>	than	1	month,	a	positive	IgM	test	alone	is	not	
recommended	for	determining	current	disease.
•	 Due	to	antibody	persistence,	single	positive	serologic	test	results	can	not	
distinguish between active and past infection and serologic tests can not be 
used	to	measure	treatment	response.
•	 Due	to	their	high	sensitivity	and	low	specificity,	EIA	and	IFA	tests	may	yield	
false-positive	results	due	to	cross-reactivity	with	antibodies	to	commensal	
or	pathogenic	spirochetes,	certain	viral	infections	(eg,	varicella,	Epstein-Barr	
virus),	or	certain	autoimmune	diseases	(eg,	systemic	lupus	erythematosus).
NOTE:  Coinfection with B. microti and/or A. phagocytophilum should be considered 
in patients who present with initial symptoms that are more severe than 
are commonly observed with Lyme disease alone, especially in those who 
have high-grade fever for more than 48 hours despite appropriate antibiotic 
therapy or who have unexplained leukopenia, thrombocytopenia, or anemia.  
Coinfection might also be considered in patients whose erythema migrans 
skin lesion has resolved but have persistent viral infection-like symptoms.
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The	regimens	listed	below	are	guidelines	only	and	may	need	to	be	adjusted	depending	on	a	patient’s	age,	medical	history,	underlying	health	conditions,	pregnancy	status	or	
allergies.		Consult	an	infectious	disease	specialist	for	the	most	current	treatment	guidelines	or	for	individual	patient	treatment	decisions.
eArly locAlizeD stAge 
AgE CATEgORy DRug DOSAgE MAxiMuM DuRATiON, DAyS (RANgE)
Adults Doxycycline 100	mg	twice	per	day N/A 14	(14-21)
Cefuroxime axetil 500	mg	twice	per	day N/A 14	(14-21)
Amoxicillin 500	mg	3	times	per	day N/A 14	(14-21)
Children Amoxicillin 50	mg/kg	per	day	in	3	divided	doses 500	mg	per	dose 14	(14-21)
Doxycycline 4	mg/kg	per	day	in	2	divided	doses 100	mg	per	dose 14	(14-21)
Cefuroxime axetil 30	mg/kg	per	day	in	2	divided	doses 500	mg	per	dose 14	(14-21)
NOTE: For patients intolerant of amoxicillin, doxycycline, and cefuroxime axetil,the macrolides azithromycin, clarithromycin, or erythromycin may be used, although they 
have a lower efficacy.  Patients treated with macrolides should be closely observed to ensure resolution of clinical manifestations.
Treatment guidelines for patients with disseminated or late stage Lyme disease are outlined in the reference below. †
Agent
BACtERIA:  borrelia burgdorferilYme Disease
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REFERENCE FOR TREATMENT GUIDELINES
Additional
Resources
Rocky mountain
Spotted Fever
TularemiaHuman granulocytic
Anaplasmosis
BabesiosisLyme
Disease
[incubAtion perioD: 1-6 weeks]
•	 Malaise,	fatigue
•	 Sustained	or	intermittent	fever,	chills
•	 Gastrointestinal	symptoms	(anorexia,	nausea,	abdominal	pain,	vomiting)
•	 Myalgia
•	 Arthralgia
•	 Depression,	emotional	lability
•	 Photophobia
•	 Conjunctival	injection
•	 Dark	urine
•	 Petechiae,	splinter	hemorrhages,	ecchymoses
•	 Mild	splenomegaly	and/or	hepatomegaly
•	 Cough
•	 Sore	throat
Agent
PARASITE:		babesia MicrotiBaBesiosis
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common finDings on routine lAborAtory tests
•	 Decreased	hematocrit	secondary	to	hemolytic	anemia
•	 Elevated	reticulocyte	counts
•	 Elevated	erythrocyte	sedimentation	rate
•	 Thrombocytopenia
•	 WBC	count	may	be	normal	or	mildly	decreased
•	 Decreased	serum	haptoglobin
•	 Elevated	serum	BUN	and	creatinine
•	 Mildly	elevated	hepatic	transaminases
•	 Proteinuria
•	 Hemoglobinuria
•	 Direct	Coombs’	test	may	react	positively
DiAgnostic lAborAtory criteriA
•	 Identification	of	intraerythrocytic	Babesia parasites in a peripheral blood 
smear; or  
•	 Isolation	of	the	parasite	from	a	whole	blood	specimen	by	animal	inoculation;	or
•	 Positive	polymerase	chain	reaction	(PCR)	assay.
NOTE: Due to the sparse parasitemia typical of most Babesia microti infections, 
additional diagnostic tests should be performed in suspect patients if the 
initial blood smear is negative.
supportive lAborAtory criteriA
•	 Demonstration	of	a	Babesia-specific	antibody	titer	by	immunofluorescence	
assay	(IFA)	test	for	IgG.		In	general,	higher	cutoff	titers	(≥	1:256)	are	associated	
with	greater	diagnostic	specificity.
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Additional
Resources
Rocky mountain
Spotted Fever
TularemiaHuman granulocytic
Anaplasmosis
Babesiosis
Agent
PARASITE:		babesia MicrotiBaBesiosis
The	regimens	listed	below	are	guidelines	only	and	may	need	to	be	adjusted	depending	on	a	patient’s	age,	medical	history,	underlying	health	conditions,	pregnancy	status	or	
allergies.		Consult	an	infectious	disease	specialist	for	the	most	current	treatment	guidelines	or	for	individual	patient	treatment	decisions.
AgE CATEgoRy DRug DoSAgE mAxImum DuRATIon (DAyS)
Adults
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Atovaquone 750	mg	orally	every	12	hours N/A 7-10
Azithromycin 500-1000	mg	on	day	1	and	250	mg	orally	once	per	day	
thereafter
N/A 7-10
OR
Pr
es
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er Clindamycin 300-600	mg	IV	every	6	hours	OR	600	mg	orally	every	8	hours N/A 7-10
Quinine 650	mg	orally	every	6-8	hours N/A 7-10
Children
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Atovaquone 20	mg/kg	every	12	hours 750	mg	per	dose 7-10
Azithromycin 10	mg/kg	once	per	day	on	day	1	and	5	mg/kg	once	per	day	
thereafter orally
500	mg	per	dose	on	day	1	and	
250	mg	per	dose	thereafter
7-10
OR
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er Clindamycin 7-10	mg/kg	IV	or	orally	every	6-8	hours 600	mg	per	dose 7-10
Quinine 8	mg/kg	orally	every	8	hours 650	mg	per	dose 7-10
NOTE: For adult patients who are immunocompromised, higher doses of azithromycin, 600-1000 mg per day, may be used.
NOTE: The recommended treatment for patients with severe babesiosis, as indicated by high-grade parasitemia (=> 10%), significant hemolysis, or renal, hepatic or 
pulmonary compromise, is quinine and IV clindamycin, and the patient should be considered for partial or complete RBC exchange transfusion.
NOTE: Consider the possibility of coinfection with B. burgdorferi and/or A. phagocytophilum in patients with especially severe or persistent symptoms, despite appropriate 
antibabesial therapy. 
NOTE: Asymptomatic patients with a positive babesial smear and/or PCR results should have these studies repeated. Treatment should be considered if parasitemia persists 
for more than three months.t
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REFERENCE FOR TREATMENT GUIDELINES
Additional
Resources
Rocky mountain
Spotted Fever
TularemiaHuman granulocytic
Anaplasmosis
Babesiosis
[incubAtion perioD 1-2 weeks]
•	 Fever,	chills
•	 Severe	headache
•	 Malaise
•	 Myalgia
•	 Gastrointestinal	symptoms	(nausea,	vomiting,	diarrhea,	anorexia)
•	 Cough
•	 Arthralgia
•	 Stiff	neck
•	 Confusion
human granulocYTic anaplasmosis
(AKA	HUMAN	GRANULOCyTIC	EHRLICHIOSIS)
Agent
BACtERIA: anaplasMa phagocytophiluM (forMerly ehrlichia phagocytophiluM)
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common finDings on routine lAborAtory tests 
generAlly observeD During the first week of clinicAl DiseAse
•	 Mild	anemia
•	 Thrombocytopenia
•	 Leukopenia	(characterized	by	relative	and	absolute	lymphopenia	and	a	left	
shift)
•	 Modest	elevations	in	hepatic	transaminases
DiAgnostic lAborAtory criteriA
•	 Demonstration	of	a	four-fold	change	in	IgG-specific	antibody	titer	by	
immunofluorescence assay (IFA) test in paired serum samples; or
•	 Detection	of	DNA	by	polymerase	chain	reaction	(PCR)	assay;	or
•	 Immunohistochemical	(IHC)	staining	of	organism;	or
•	 Isolation	of	organism	from	a	clinical	specimen.
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NOTE: Visualization of morulae in the cytoplasm of neutrophils or eosinophils during 
examination of blood smears is highly suggestive of a diagnosis; however, 
blood smear examination is insensitive and should never be relied upon 
solely to rule HGA in or out. 
NOTE: Confirmation of the diagnosis is based on laboratory testing, but antibiotic 
therapy should not be delayed in a patient with a suggestive clinical 
presentation.
NOTE: Consider the possibility of coinfection with B. microti and/or B. burgdorferi.
Additional
Resources
Rocky mountain
Spotted Fever
TularemiaHuman granulocytic
Anaplasmosis
The	regimens	listed	below	are	guidelines	only	and	may	need	to	be	adjusted	depending	on	a	patient’s	age,	medical	history,	underlying	health	conditions,	pregnancy	status	or	
allergies.		Consult	an	infectious	disease	specialist	for	the	most	current	treatment	guidelines	or	for	individual	patient	treatment	decisions.
AgE CATEgoRy DRug DoSAgE mAxImum DuRATIon (DAyS)
Adults Doxycycline 100	mg	twice	per	day	orally	or	IV N/A 10
Children
8	years	of	age	or	older
moderate illness
Doxycycline 4	mg/kg	per	day	orally	or	IV	in	2	divided	
doses
100	mg	per	dose 10
Children
less	than	8	years	of	age
severe illness
without	Lyme	disease
Doxycycline 4	mg/kg	per	day	orally	or	IV	in	2	divided	
doses
100	mg	per	dose 4-5	
OR	approx.	3	days	after	resolution	
of fever
Children 
less	than	8	years	of	age
severe illness
with	Lyme	disease
Doxycycline 4	mg/kg	per	day	given	orally	or	IV	in	2	
divided doses
100	mg	per	dose 4-5
Fo
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Amoxicillin 50	mg/kg	per	day	in	3	divided	doses 500	mg	per	dose to	complete	a	14	day	total	course	of	
antibiotic therapy
OR
Cefuroxime axetil 30	mg/kg	per	day	in	2	divided	doses 500	mg	per	dose to	complete	a	14	day	total	course	of	
antibiotic therapy
NOTE: Patients with mild illness for whom doxycycline treatment is contraindicated may be treated with rifampin for 7-10 days using a dosage regimen of 300 mg twice per 
day by mouth for adults and 10 mg/kg twice per day for children (maximum, 300 mg per dose).
NOTE: Because HGA can be life-threatening and limited courses of therapy do not pose a substantial risk for tooth staining, the American Academy of Pediatrics has 
identified doxycycline as the drug of choice for treating HGA in children of any age.
NOTE: Treatment response is expected within 48 hours.
NOTE: Treatment is not recommended for asymptomatic individuals who are seropositive for antibodies to A. phagocytophilum.
human granulocYTic anaplasmosis
(AKA	HUMAN	GRANULOCyTIC	EHRLICHIOSIS)
Agent
BACtERIA: anaplasMa phagocytophiluM (forMerly ehrlichia phagocytophiluM)
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REFERENCE FOR TREATMENT GUIDELINES
Additional
Resources
Rocky mountain
Spotted Fever
TularemiaHuman granulocytic
Anaplasmosis
[AverAge incubAtion perioD 3-5 DAys, rAnge 1-21 DAys]
NOTE: The clinical presentation of tularemia will depend on a number of factors, 
including the portal of entry.
generAl (mAy be present in All forms of tulAremiA)
•	 Fever,	chills
•	 Headache
•	 Malaise,	fatigue
•	 Anorexia
•	 Myalgia
•	 Chest	discomfort,	cough
•	 Sore	throat
•	 Vomiting,	diarrhea
•	 Abdominal	pain
ulceroglAnDulAr
•	 Localized	lymphadenopathy
•	 Cutaneous	ulcer	at	infection	site
glAnDulAr
•	 Regional	lymphadenopathy	with	no	cutaneous	lesion
typhoiDAl
•	 Characterized	by	any	combination	of	the	general	symptoms
oculoglAnDulAr
•	 Photophobia
•	 Excessive	lacrimation
•	 Conjunctivitis
•	 Preauricular,	submandibular	and	cervical	lymphadenopathy
phAryngeAl
•	 Severe	throat	pain
•	 Cervical,	preparotid,	and	retropharyngeal	lymphadenopathy
pneumonic
•	 Non-productive	cough
•	 Substernal	tightness
•	 Pleuritic	chest	pain
NOTE: Pneumonic tularemia should be considered in any patient presenting with 
community-acquired pneumonia who resides on, or has recently visited, 
Martha’s Vineyard.
Agent
BACtERIA:  francisella  tularensisTularemia
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common finDings on routine lAborAtory tests 
•	 Leukocyte	count	and	sedimentation	rate	may	be	normal	or	elevated
•	 Thrombocytopenia
•	 Hyponatremia
•	 Elevated	hepatic	transaminases
•	 Elevated	creatine	phosphokinase
•	 Myoglobinuria
•	 Sterile	pyuria
L
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DiAgnostic lAborAtory criteriA
•	 Demonstration	of	a	four-fold	change	in	antibody	titer	in	paired	sera;	or
•	 Isolation	of	organism.
NOTE: Detection of organism by immunofluorescence assay (IFA) test or a single 
elevated serum antibody titer is supportive of the diagnosis; however, these 
results should be confirmed by either one of the methods above.
Additional
Resources
Rocky mountain
Spotted Fever
Tularemia
The	regimens	listed	below	are	guidelines	only	and	may	need	to	be	adjusted	depending	on	a	patient’s	age,	medical	history,	underlying	health	conditions,	pregnancy	status	or	
allergies.		Consult	an	infectious	disease	specialist	for	the	most	current	treatment	guidelines	or	for	individual	patient	treatment	decisions.
AgE CATEgoRy DRug DoSAgE mAxImum DuRATIon, DAyS
Adults Gentamicin 5	mg/kg	IM	or	IV	daily	(with	desired	peak	serum	
levels	of	at	least	5	mcg/mL)
N/A 10
OR
Streptomycin 1	g	IM	twice	daily	 N/A 10	
Children Gentamicin 2.5	mg/kg	IM	or	IV	3	times	daily Consult a pediatric infectious disease specialist 10
OR
Streptomycin 15	mg/kg	IM	twice	daily 2	g/day 10
NOTE: Doses of both streptomycin and gentamicin need to be adjusted for renal insufficiency.
NOTE: Chloramphenicol may be added to streptomycin to treat meningitis.
NOTE: Alternative therapies to the preferred regimens of streptomycin and gentamicin are outlined in the reference below. †
Agent
BACtERIA:  francisella  tularensisTularemia
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RefeRences
Centers	for	Disease	Control	and	Prevention.		Case	definitions	for	infectious	conditions	under	public	health	surveillance.		www.cdc.gov/epo/dphsi/casedef/case_definitions.
htm.		Downloaded	1/11/08.
Dennis	D.,	Inglesby	TV.,	Henderson	DA.,	et	al.		Tularemia	as	a	Biological	Weapon:	Medical	and	Public	Health	Management.		Journal	of	the	American	Medical	Association.		2001.	
285(21):	2763-2773.
Feldman	KA.,	Enscore	RE,	Lathrop	SL.,	et	al.		An	Outbreak	of	Primary	Pneumonic	Tularemia	on	Martha’s	Vineyard.		New	England	Journal	of	Medicine.		2001;	345:	1601-1606.
Penn	RL.		Francisella tularensis	(Tularemia).		In:	Mandell	GL,	Bennett	JE,	Dolin	R,	editors.		Mandell,	Douglas,	and	Bennett’s	Principles	and	Practice	of	Infectious	Diseases.		6th 
ed.		Philadelphia,	PA:	Churchill	Livingstone;	2005.	p.	2674-2685.
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Additional
Resources
Rocky mountain
Spotted Fever
Tularemia
rockY mounTain spoTTeD fever
[incubAtion perioD 2-14 DAys]
•	 Fever, chills
•	 Severe	headache
•	 Malaise
•	 Myalgia
•	 Gastrointestinal	symptoms	(nausea,	vomiting,	anorexia,	abdominal	pain,	
diarrhea, abdominal tenderness)
•	 Rash,	2-5	days	after	fever	starts,	begins	as	small,	blanching,	pink	macules	
on	the	ankles,	wrists,	or	forearms	that	evolve	to	maculopapules.		May	expand	
to	the	entire	body	including	the	palms	and	soles.		The	classic	spotted,	or	
generalized	petechial,	rash	is	not	usually	apparent	until	the	5th	or	6th	day	of	
illness.
•	 Cough
•	 Conjunctival	injection,	+/-photophobia
•	 Altered	mental	status
•	 Focal	neurologic	deficits,	including	cranial	or	peripheral	motor	nerve	paralysis	
or sudden transient deafness 
NOTE: Rash may be completely absent or atypical in up to 20% of RMSF cases.  
Rocky Mountain “spotless” fever is more likely to occur in older patients.
Agent
BACtERIA:  rickettsia rickettsii
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common finDings on routine lAborAtory tests
•	 Anemia
•	 Thrombocytopenia
•	 Mildly	elevated	hepatic	transaminase	levels	
•	 Hyponatremia
•	 Azotemia
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DiAgnostic lAborAtory criteriA
•	 Demonstration	of	a	four-fold	change	in	IgG-specific	antibody	titer	by	
immunofluorescence assay (IFA) test in paired sera; or
•	 Detection	of	DNA	in	a	clinical	specimen	by	polymerase	chain	reaction	(PCR)	
assay (generally unreliable for acute blood samples); or
•	 Immunohistochemical	(IHC)	staining	of	organism	in	a	biopsy	or	autopsy	
specimen; or
•	 Isolation	of	organism	in	cell	culture.
NOTE: Tests for IgM antibodies are generally not useful for serodiagnosis of acute 
disease, due to cross-reactivity and persistence of the antibody.
NOTE: Confirmation of the diagnosis is based on laboratory testing, but antibiotic 
therapy should not be delayed in a patient with a suggestive clinical 
presentation.
Additional
Resources
Rocky mountain
Spotted Fever
The	regimens	listed	below	are	guidelines	only	and	may	need	to	be	adjusted	depending	on	a	patient’s	age,	medical	history,	underlying	health	conditions,	pregnancy	status	or	
allergies.		Consult	an	infectious	disease	specialist	for	the	most	current	treatment	guidelines	or	for	individual	patient	treatment	decisions.
AgE CATEgoRy DRug DoSAgE mAxImum DuRATIon (DAyS)
Adults Doxycycline 100	mg	twice	daily,	orally	or	IV N/A At	 least	 3	 days	 after	 the	 fever	 subsides	 and	 until	 evidence	 of	
clinical improvement is noted which is typically for a minimum 
total	course	of	5-7	days.
Children	weighing	=>100	lbs	
(45.4kg)
Doxycycline 100	mg	twice	daily,	orally	or	IV Consult a pediatric infectious 
disease specialist
At	 least	 3	 days	 after	 the	 fever	 subsides	 and	 until	 evidence	 of	
clinical improvement is noted which is typically for a minimum 
total	course	of	5-7	days.
Children	weighing	<	100	lbs	
(45.4kg)
Doxcycline 2.2	mg/kg	body	weight	per	dose	twice	
daily,	orally	or	IV
Consult a pediatric infectious 
disease specialist
At	 least	 3	 days	 after	 the	 fever	 subsides	 and	 until	 evidence	 of	
clinical improvement is noted which is typically for a minimum 
total	course	of	5-7	days.
NOTE: Because RMSF can be life-threatening and limited courses of therapy do not pose a substantial risk for tooth staining, the American Academy of Pediatrics has 
identified doxycycline as the drug of choice for treating RMSF in children of any age.
rockY mounTain spoTTeD fever AgentBACtERIA:  rickettsia rickettsii
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Centers	for	Disease	Control	and	Prevention.		Diagnosis	and	management	of	tickborne	rickettsial	diseases:		Rocky	Mountain	spotted	fever,	ehrlichiosis,	and	anaplasmosis—
United	States:	a	practical	guide	for	physicians	and	other	health-care	and	public	health	professionals.		MMWR	2006;	55	(No.	RR-4).
Engel	J,	Bradley	K.,	et	al.		Revision	of	the	National	Surveillance	Case	Definition	for	Rocky	Mountain	spotted	fever.		Council	of	State	and	Territorial	Epidemiologists,	Infectious	
Diseases	Committee,	2007	Position	Statement.		www.cste.org/PS/2007ps/2007psfinal/ID/07-ID-05.pdf
Walker	DH,	Raoult	D.		Rickettsia ricketsii	and	Other	Spotted	Fever	Group	Rickettsiae	(Rocky	Mountain	Spotted	Fever	and	Other	Spotted	Fevers).		In:	Mandell	GL,	Bennett	JE,	
Dolin	R,	editors.		Mandell,	Douglas,	and	Bennett’s	Principles	and	Practice	of	Infectious	Diseases.		6th	ed.		Philadelphia,	PA:	Churchill	Livingstone;	2005.	p.	2287-2295.
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Additional
Resources
Rocky mountain
Spotted Fever
foR moRe infoRmation on tickboRne diseases:
Massachusetts Department of Public Health
Division	of	Epidemiology	and	Immunization
617-983-6800
www.mass.gov/dph/epi
Centers for Disease Control and Prevention
www.cdc.gov
American College of Physicians/American Society of internal Medicine 
http://www.acponline.org/lyme/ 
to RepoRt a case of tickboRne disease oR obtain infoRmation on the numbeR of 
cases of tickboRne diseases in youR aRea:
Massachusetts Department of Public Health
Office	of	Integrated	Surveillance	and	Informatics	Services
617-983-6801
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